Morphic Holding, Inc.
Morphic Holding, Inc. (MORF): 2 pipeline candidates · ~21 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
21.3 months
D/E 0.04 · 0% dilution
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for Morphic Holding, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$51.4M
Quarterly Burn
$32.1M
Runway
21.3 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in Morphic Holding, Inc.'s pipeline?
Morphic Holding, Inc. (MORF) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Morphic Holding, Inc.'s lead drug candidate?
Morphic Holding, Inc.'s most advanced tracked candidate is morf-057 (Phase 2) for Inflammatory bowel disease (IBD), specifically ulcerative colitis (UC).
What is Morphic Holding, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Morphic Holding, Inc. has approximately 21.3 months of cash runway.
Who is the CEO of Morphic Holding, Inc.?
Praveen P. Tipirneni, M.D. is the chief executive officer of Morphic Holding, Inc. (MORF).
Get the full picture on Morphic Holding, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.